DK2544537T3 - PARENTERAL FORMULATIONS OF MACROLIDE ANTIBIOTICS - Google Patents

PARENTERAL FORMULATIONS OF MACROLIDE ANTIBIOTICS Download PDF

Info

Publication number
DK2544537T3
DK2544537T3 DK11754115.1T DK11754115T DK2544537T3 DK 2544537 T3 DK2544537 T3 DK 2544537T3 DK 11754115 T DK11754115 T DK 11754115T DK 2544537 T3 DK2544537 T3 DK 2544537T3
Authority
DK
Denmark
Prior art keywords
composition
cem
pharmaceutical composition
another embodiment
administration
Prior art date
Application number
DK11754115.1T
Other languages
Danish (da)
English (en)
Inventor
David E Pereira
Prabhavathi Fernandes
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2544537T3 publication Critical patent/DK2544537T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK11754115.1T 2010-03-10 2011-03-10 PARENTERAL FORMULATIONS OF MACROLIDE ANTIBIOTICS DK2544537T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31241710P 2010-03-10 2010-03-10
PCT/US2011/027984 WO2011112864A1 (en) 2010-03-10 2011-03-10 Parenteral formulations of macrolide antibiotics

Publications (1)

Publication Number Publication Date
DK2544537T3 true DK2544537T3 (en) 2017-08-28

Family

ID=44563855

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11754115.1T DK2544537T3 (en) 2010-03-10 2011-03-10 PARENTERAL FORMULATIONS OF MACROLIDE ANTIBIOTICS

Country Status (11)

Country Link
US (3) US20130045937A1 (enExample)
EP (1) EP2544537B1 (enExample)
JP (1) JP5890785B2 (enExample)
CN (2) CN102811616A (enExample)
AU (1) AU2011224238B2 (enExample)
CA (1) CA2792616A1 (enExample)
DK (1) DK2544537T3 (enExample)
ES (1) ES2637072T3 (enExample)
PL (1) PL2544537T3 (enExample)
SI (1) SI2544537T1 (enExample)
WO (1) WO2011112864A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529817C (en) 2003-03-10 2013-02-12 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
WO2010048601A1 (en) 2008-10-24 2010-04-29 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CN102724874B (zh) * 2009-09-10 2018-06-01 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
US8975386B2 (en) 2010-03-22 2015-03-10 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses therefor
EP2571506B1 (en) 2010-05-20 2017-05-10 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
KR20180110181A (ko) 2010-09-10 2018-10-08 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
CN104470527B (zh) * 2012-03-27 2019-05-28 森普拉制药公司 用于施用大环内酯抗生素的肠胃外制剂
CN105163785A (zh) * 2013-03-14 2015-12-16 森普拉制药公司 用于治疗呼吸道疾病的方法及其制剂
WO2014145210A1 (en) 2013-03-15 2014-09-18 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
EP2988597B1 (en) 2013-04-04 2022-06-08 President and Fellows of Harvard College Macrolides and methods of their preparation and use
ES2743617T3 (es) 2013-05-22 2020-02-20 Zensun Shanghai Science & Tech Co Ltd Liberación prolongada de neuregulina para tratar la insuficiencia cardíaca
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
SG11201700827RA (en) * 2014-08-05 2017-03-30 Cempra Pharmaceuticals Inc Powder oral suspension formulations of antibacterial agents
US10633407B2 (en) 2014-10-08 2020-04-28 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3273969A4 (en) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
CA3144443A1 (en) * 2019-06-28 2020-12-30 Moleculin Biotech, Inc. Method of reconstituting liposomal annamycin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
WO2003072141A1 (en) * 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
CA2529817C (en) * 2003-03-10 2013-02-12 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
CN101045063B (zh) * 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方

Also Published As

Publication number Publication date
CN109091489A (zh) 2018-12-28
EP2544537A4 (en) 2014-05-14
JP5890785B2 (ja) 2016-03-22
SI2544537T1 (sl) 2017-12-29
AU2011224238B2 (en) 2015-11-26
ES2637072T3 (es) 2017-10-10
US20130045937A1 (en) 2013-02-21
CN102811616A (zh) 2012-12-05
AU2011224238A1 (en) 2012-10-04
PL2544537T3 (pl) 2017-10-31
CA2792616A1 (en) 2011-09-15
US20190054059A1 (en) 2019-02-21
US20200276150A1 (en) 2020-09-03
JP2013522229A (ja) 2013-06-13
EP2544537B1 (en) 2017-05-10
WO2011112864A1 (en) 2011-09-15
EP2544537A1 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
DK2544537T3 (en) PARENTERAL FORMULATIONS OF MACROLIDE ANTIBIOTICS
US10188674B2 (en) Parenteral formulations for administering macrolide antibiotics
US20180169106A1 (en) Ceftolozane-tazobactam pharmaceutical compositions
ES2638113T3 (es) Conservantes antimicrobianos para lograr una formulación de dosis múltiples usando ciclodextrinas beta para formas de dosificación líquidas
HK1180184A (en) Parenteral formulations of macrolide antibiotics
HK1180184B (en) Parenteral formulations of macrolide antibiotics
HK40002820A (en) Parenteral formulations of macrolide antibiotics
HK1179115A (en) Parenteral formulations of macrolide antibiotics
AU2018220172A1 (en) Triazole-containing macrolides and ophthalmic uses therefor
HK1208622B (zh) 用於施用大环内酯抗生素的肠胃外制剂
AU2018230347A1 (en) Compositions and methods for treating dry eye diseases